Yuhan’s Leclaza combination tops $300 mn in quarterly sales for first time

South Korean pharmaceutical company Yuhan Corp.’s lung cancer drug Leclaza is gaining momentum in global markets, with quarterly sales of its combination therapy with Johnson & Johnson’s Rybrevant surpassing $300 million for the first time.

Growth has been particularly strong outside the United States, where sales nearly doubled from a year earlier, highlighting the treatment’s expanding international reach.

Johnson & Johnson (J&J) said in its third-quarter earnings report released Tuesday local time that global sales of the Rybrevant-Leclaza combination reached $320 million, up 62.3 percent from a year earlier and 10.7 percent from the previous quarter.

Quarterly sales rose from $198 million in the third quarter of last year to $257 million in the first quarter of 2026 and $289 million in the second quarter before exceeding $300 million for the first time in the July-September period.

Sales in the United States totaled $201 million, an increase of 47.9 percent from a year earlier.

Revenue outside the United States surged 94.5 percent to $119 million, nearly twice the growth rate recorded in the U.S. market.

As a result, overseas markets accounted for approximately 37 percent of total sales in the third quarter, up from about 31 percent a year earlier.

Cumulative global sales for the first nine months of 2026 reached $866 million, up 67.4 percent from the same period last year.

Sales outside the United States totaled $300 million during the period, representing a 130.8 percent increase.

With cumulative sales already exceeding $800 million through September, the combination therapy is increasingly likely to surpass $1 billion in annual sales.

J&J has also secured regulatory approvals for Rybrevant Faspro, a subcutaneous formulation designed to shorten administration time compared with the existing intravenous (IV) version, in more than 40 countries, including the United States, European countries, Japan and China.

While the initial infusion of the IV formulation takes approximately five hours, the subcutaneous version can be administered in about five minutes, offering significantly greater convenience for patients undergoing treatment.